Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Hansa Medical in connection with a directed share issue
Mandate

Vinge advises Hansa Medical in connection with a directed share issue

November 15, 2018 Capital Markets and Public M&A

The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hansa Medical will raise proceeds of approximately SEK 453 / USD 50 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Cowen, RBC Capital Markets and Skandinaviska Enskilda Banken.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg and Edin Agic. 
 

Related

Vinge has advised Main Capital and Pointsharp in connection with the acquisition of Meaplus AB and Nubibus Software AB

 Vinge has advised Main Capital and its portfolio company Pointsharp in connection with Pointsharp's acquisition of Meaplus AB and Nubibus Software AB. Pointsharp is a Swedish provider of identity and access management solutions as well as secure information exchange, with operations in the Nordics, DACH and Benelux. The acquisition complements Pointsharp's existing offering with capabilities in secure digital communication and strengthens the company's position in the Swedish public-sector market, particularly in the municipal and healthcare segments. The transaction is Pointsharp's sixth add-on acquisition since Main Capital became an investment partner in November 2020.
October 01, 2026

Vinge has advised Main Capital Partners on the acquisition of Confirma Software

 Confirma Software (“Confirma”) is a Nordic vertical software group providing mission-critical B2B software to SMEs in Sweden, Finland, Norway and Denmark. The company operates across five complementary software areas: ERP, Payment Solutions, Financial Solutions, Quality Management Systems and Business Process Solutions. Confirma was founded in 2019 and is headquartered in Stockholm. Supported by approximately 540 professionals, the company serves more than 25,000 customers, including over 500 municipalities, across the Nordics. By combining deep local domain expertise with software embedded in customers’ day-to-day operations, Confirma has developed long-standing customer relationships and a highly recurring revenue profile.
September 25, 2026

Vinge has advised Embracer Group in connection with a SEK 2 billion multicurrency revolving credit facility agreement entered into with SEB, DNB, Nordea and Swedbank

 Vinge has advised Embracer Group AB (publ) (“Embracer”) in connection with the entry into of a SEK 2,000,000,000 financing agreement with SEB, DNB, Nordea and Swedbank. Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry.
September 25, 2026